TIGIT

Note

TIGIT 타겟 임상시험 모니터링

Visual Summary

Change History

  • 2026-04-10 02:59:15: Changes detected in 1 trials: NCT07161414
  • 2026-04-09 02:48:37: Changes detected in 3 trials: NCT06346197, NCT06989112, NCT04305054
  • 2026-04-04 02:41:58: Changes detected in 11 trials: NCT05327530, NCT06334406, NCT06302556, NCT05645692, NCT05676931, NCT04543617, NCT04305041, NCT06692738, NCT04256421, NCT04305054, NCT04294810
  • 2026-04-03 02:39:33: Changes detected in 1 trials: NCT05568095
  • 2026-04-01 03:02:47: Changes detected in 3 trials: NCT05394168, NCT05130177, NCT06692738
  • 2026-03-31 02:51:38: Changes detected in 3 trials: NCT04736173, NCT05329766, NCT06996782
  • 2026-03-28 02:42:32: Changes detected in 1 trials: NCT06627647
  • 2026-03-26 02:49:53: Changes detected in 1 trials: NCT06346197
  • 2026-03-25 02:43:26: Changes detected in 1 trials: NCT04995523
  • 2026-03-24 02:31:07: Changes detected in 2 trials: NCT06713798, NCT05123482

NCT05394168

  • 2026-04-01 02:42:41 (Trial Update)
    • Field `statusModule.overallStatus` changed from `ACTIVE_NOT_RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT04995523

  • 2026-03-25 02:23:20 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-03`
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-08-18` to `2026-08-28`
    • Field `statusModule.completionDateStruct.date` changed from `2028-03-16` to `2028-06-01`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-21` to `2026-03-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-24` to `2026-03-24`
    • Field `designModule.enrollmentInfo.count` changed from `210` to `212`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `contactsLocationsModule.locations.[1]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60637', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}` to `{'facility': 'Research Site', 'city': 'Rochester', 'state': 'Minnesota', 'zip': '55905', 'country': 'United States', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}`
    • Field `contactsLocationsModule.locations.[20]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Tbilisi', 'zip': '0112', 'country': 'Georgia', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}` to `{'facility': 'Research Site', 'city': 'Tokyo', 'zip': '104-0045', 'country': 'Japan', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}`
    • Field `contactsLocationsModule.locations.[3]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Rochester', 'state': 'Minnesota', 'zip': '55905', 'country': 'United States', 'geoPoint': {'lat': 44.02163, 'lon': -92.4699}}` to `{'facility': 'Research Site', 'city': 'Melbourne', 'zip': '3000', 'country': 'Australia', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}`
    • Field `contactsLocationsModule.locations.[11]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Porto Alegre', 'zip': '90035903', 'country': 'Brazil', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}` to `{'facility': 'Research Site', 'city': 'Chengdu', 'zip': '610041', 'country': 'China', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}`
    • Field `contactsLocationsModule.locations.[4]` changed from `{'facility': 'Research Site', 'status': 'WITHDRAWN', 'city': 'Houston', 'state': 'Texas', 'zip': '77030', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}` to `{'facility': 'Research Site', 'city': 'Anderlecht', 'zip': '1070', 'country': 'Belgium', 'geoPoint': {'lat': 50.83619, 'lon': 4.31454}}`
    • Field `contactsLocationsModule.locations.[19]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Toulouse', 'zip': '31059', 'country': 'France', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}` to `{'facility': 'Research Site', 'city': 'Sendai', 'zip': '981-0914', 'country': 'Japan', 'geoPoint': {'lat': 38.26667, 'lon': 140.86667}}`
    • Field `contactsLocationsModule.locations.[13]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'São Paulo', 'zip': '01246-000', 'country': 'Brazil', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}` to `{'facility': 'Research Site', 'city': 'Copenhagen', 'zip': '2100', 'country': 'Denmark', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}`
    • Field `contactsLocationsModule.locations.[2]` changed from `{'facility': 'Research Site', 'status': 'WITHDRAWN', 'city': 'Baltimore', 'state': 'Maryland', 'zip': '21201', 'country': 'United States', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}` to `{'facility': 'Research Site', 'city': 'Fairfax', 'state': 'Virginia', 'zip': '22031', 'country': 'United States', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}`
    • Field `contactsLocationsModule.locations.[6]` changed from `{'facility': 'Research Site', 'status': 'COMPLETED', 'city': 'Melbourne', 'zip': '3000', 'country': 'Australia', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}` to `{'facility': 'Research Site', 'city': 'Florianópolis', 'zip': '88034-000', 'country': 'Brazil', 'geoPoint': {'lat': -27.59667, 'lon': -48.54917}}`
    • Field `contactsLocationsModule.locations.[5]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Fairfax', 'state': 'Virginia', 'zip': '22031', 'country': 'United States', 'geoPoint': {'lat': 38.84622, 'lon': -77.30637}}` to `{'facility': 'Research Site', 'city': 'Leuven', 'zip': '3000', 'country': 'Belgium', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}`
    • Field `contactsLocationsModule.locations.[39]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Taichung', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}` to `{'facility': 'Research Site', 'city': 'Muang', 'zip': '50200', 'country': 'Thailand'}`
    • Field `contactsLocationsModule.locations.[18]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Dijon', 'zip': '21079', 'country': 'France', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}` to `{'facility': 'Research Site', 'city': 'Niigata', 'zip': '951-8566', 'country': 'Japan', 'geoPoint': {'lat': 37.92259, 'lon': 139.04125}}`
    • Field `contactsLocationsModule.locations.[12]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Rio de Janeiro', 'zip': '20231-050', 'country': 'Brazil', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}` to `{'facility': 'Research Site', 'city': 'Chongqing', 'zip': '400030', 'country': 'China', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}`
    • Field `contactsLocationsModule.locations.[10]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Natal', 'zip': '59075-740', 'country': 'Brazil', 'geoPoint': {'lat': -5.795, 'lon': -35.20944}}` to `{'facility': 'Research Site', 'city': 'São Paulo', 'zip': '01246-000', 'country': 'Brazil', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}`
    • Field `contactsLocationsModule.locations.[25]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Kuala Lumpur', 'zip': '59100', 'country': 'Malaysia', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}` to `{'facility': 'Research Site', 'city': 'Leiden', 'zip': '2333 ZA', 'country': 'Netherlands', 'geoPoint': {'lat': 52.15833, 'lon': 4.49306}}`
    • Field `contactsLocationsModule.locations.[27]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Chisinau', 'zip': 'MD-2025', 'country': 'Moldova', 'geoPoint': {'lat': 47.00902, 'lon': 28.85938}}` to `{'facility': 'Research Site', 'city': 'Seoul', 'zip': '03082', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}`
    • Field `contactsLocationsModule.locations.[9]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Florianópolis', 'zip': '88034-000', 'country': 'Brazil', 'geoPoint': {'lat': -27.59667, 'lon': -48.54917}}` to `{'facility': 'Research Site', 'city': 'Rio de Janeiro', 'zip': '20231-050', 'country': 'Brazil', 'geoPoint': {'lat': -22.90642, 'lon': -43.18223}}`
    • Field `contactsLocationsModule.locations.[32]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '03082', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}` to `{'facility': 'Research Site', 'city': 'Madrid', 'zip': '28041', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}`
    • Field `contactsLocationsModule.locations.[7]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Anderlecht', 'zip': '1070', 'country': 'Belgium', 'geoPoint': {'lat': 50.83619, 'lon': 4.31454}}` to `{'facility': 'Research Site', 'city': 'Natal', 'zip': '59075-740', 'country': 'Brazil', 'geoPoint': {'lat': -5.795, 'lon': -35.20944}}`
    • Field `contactsLocationsModule.locations.[17]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Copenhagen', 'zip': '2100', 'country': 'Denmark', 'geoPoint': {'lat': 55.67594, 'lon': 12.56553}}` to `{'facility': 'Research Site', 'city': 'Kashiwa', 'zip': '227-8577', 'country': 'Japan', 'geoPoint': {'lat': 35.86224, 'lon': 139.97732}}`
    • Field `contactsLocationsModule.locations.[8]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Leuven', 'zip': '3000', 'country': 'Belgium', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}` to `{'facility': 'Research Site', 'city': 'Porto Alegre', 'zip': '90035903', 'country': 'Brazil', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}`
    • Field `contactsLocationsModule.locations.[14]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Chengdu', 'zip': '610041', 'country': 'China', 'geoPoint': {'lat': 30.66667, 'lon': 104.06667}}` to `{'facility': 'Research Site', 'city': 'Dijon', 'zip': '21079', 'country': 'France', 'geoPoint': {'lat': 47.31344, 'lon': 5.01391}}`
    • Field `contactsLocationsModule.locations.[28]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Groningen', 'zip': '9713 GZ', 'country': 'Netherlands', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}` to `{'facility': 'Research Site', 'city': 'Seoul', 'zip': '03722', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}`
    • Field `contactsLocationsModule.locations.[15]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Chongqing', 'zip': '400030', 'country': 'China', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}` to `{'facility': 'Research Site', 'city': 'Toulouse', 'zip': '31059', 'country': 'France', 'geoPoint': {'lat': 43.60426, 'lon': 1.44367}}`
    • Field `contactsLocationsModule.locations.[26]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Kuching', 'zip': '93586', 'country': 'Malaysia', 'geoPoint': {'lat': 1.55, 'lon': 110.33333}}` to `{'facility': 'Research Site', 'city': 'Utrecht', 'zip': '3584 CX', 'country': 'Netherlands', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}`
    • Field `contactsLocationsModule.locations.[24]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Tokyo', 'zip': '104-0045', 'country': 'Japan', 'geoPoint': {'lat': 35.6895, 'lon': 139.69171}}` to `{'facility': 'Research Site', 'city': 'Groningen', 'zip': '9713 GZ', 'country': 'Netherlands', 'geoPoint': {'lat': 53.21917, 'lon': 6.56667}}`
    • Field `contactsLocationsModule.locations.[29]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Leiden', 'zip': '2333 ZA', 'country': 'Netherlands', 'geoPoint': {'lat': 52.15833, 'lon': 4.49306}}` to `{'facility': 'Research Site', 'city': 'Seoul', 'zip': '05505', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}`
    • Field `contactsLocationsModule.locations.[23]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Sendai', 'zip': '981-0914', 'country': 'Japan', 'geoPoint': {'lat': 38.26667, 'lon': 140.86667}}` to `{'facility': 'Research Site', 'city': 'Chisinau', 'zip': 'MD-2025', 'country': 'Moldova', 'geoPoint': {'lat': 47.00902, 'lon': 28.85938}}`
    • Field `contactsLocationsModule.locations.[21]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Kashiwa', 'zip': '227-8577', 'country': 'Japan', 'geoPoint': {'lat': 35.86224, 'lon': 139.97732}}` to `{'facility': 'Research Site', 'city': 'Kuala Lumpur', 'zip': '59100', 'country': 'Malaysia', 'geoPoint': {'lat': 3.1412, 'lon': 101.68653}}`
    • Field `contactsLocationsModule.locations.[33]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '03722', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}` to `{'facility': 'Research Site', 'city': 'Taichung', 'zip': '40201', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}`
    • Field `contactsLocationsModule.locations.[0]` changed from `{'facility': 'Research Site', 'status': 'WITHDRAWN', 'city': 'Orange', 'state': 'California', 'zip': '92868', 'country': 'United States', 'geoPoint': {'lat': 33.78779, 'lon': -117.85311}}` to `{'facility': 'Research Site', 'city': 'Chicago', 'state': 'Illinois', 'zip': '60637', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}`
    • Field `contactsLocationsModule.locations.[35]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Barcelona', 'zip': '08035', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}` to `{'facility': 'Research Site', 'city': 'Tainan', 'zip': '70403', 'country': 'Taiwan', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}`
    • Field `contactsLocationsModule.locations.[22]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Niigata', 'zip': '951-8566', 'country': 'Japan', 'geoPoint': {'lat': 37.92259, 'lon': 139.04125}}` to `{'facility': 'Research Site', 'city': 'Kuching', 'zip': '93586', 'country': 'Malaysia', 'geoPoint': {'lat': 1.55, 'lon': 110.33333}}`
    • Field `contactsLocationsModule.locations.[36]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Madrid', 'zip': '28027', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}` to `{'facility': 'Research Site', 'city': 'Taipei', 'zip': '110', 'country': 'Taiwan', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}`
    • Field `contactsLocationsModule.locations.[38]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Taichung', 'zip': '40201', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}` to `{'facility': 'Research Site', 'city': 'Chanthaburi', 'zip': '22000', 'country': 'Thailand', 'geoPoint': {'lat': 12.60961, 'lon': 102.10447}}`
    • Field `contactsLocationsModule.locations.[34]` changed from `{'facility': 'Research Site', 'status': 'RECRUITING', 'city': 'Seoul', 'zip': '05505', 'country': 'South Korea', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}` to `{'facility': 'Research Site', 'city': 'Taichung', 'country': 'Taiwan', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}`
    • Field `contactsLocationsModule.locations.[16]` changed from `{'facility': 'Research Site', 'status': 'WITHDRAWN', 'city': 'Wuhan', 'zip': '430022', 'country': 'China', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}` to `{'facility': 'Research Site', 'city': 'Tbilisi', 'zip': '0112', 'country': 'Georgia', 'geoPoint': {'lat': 41.69143, 'lon': 44.83412}}`
    • Field `contactsLocationsModule.locations.[30]` changed from `{'facility': 'Research Site', 'status': 'COMPLETED', 'city': 'Utrecht', 'zip': '3584 CX', 'country': 'Netherlands', 'geoPoint': {'lat': 52.09083, 'lon': 5.12222}}` to `{'facility': 'Research Site', 'city': 'Barcelona', 'zip': '08035', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}`
    • Field `contactsLocationsModule.locations.[37]` changed from `{'facility': 'Research Site', 'status': 'ACTIVE_NOT_RECRUITING', 'city': 'Madrid', 'zip': '28041', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}` to `{'facility': 'Research Site', 'city': 'Bangkok', 'zip': '10700', 'country': 'Thailand', 'geoPoint': {'lat': 13.75398, 'lon': 100.50144}}`
    • Field `contactsLocationsModule.locations.[31]` changed from `{'facility': 'Research Site', 'status': 'WITHDRAWN', 'city': 'Singapore', 'zip': '308433', 'country': 'Singapore', 'geoPoint': {'lat': 1.28967, 'lon': 103.85007}}` to `{'facility': 'Research Site', 'city': 'Madrid', 'zip': '28027', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}`
    • Field removed: `root['contactsLocationsModule']['centralContacts']`

NCT05130177

  • 2026-04-01 02:42:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-05` to `2026-03`
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2028-01` to `2026-02-06`
    • Field `statusModule.primaryCompletionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.completionDateStruct.date` changed from `2031-01` to `2030-01-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-05-02` to `2026-03-25`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-05-07` to `2026-03-31`
    • Field `designModule.enrollmentInfo.count` changed from `26` to `8`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • Field removed: `root['statusModule']['expandedAccessInfo']`
    • Field removed: `root['oversightModule']['isUsExport']`
    • Field removed: `root['contactsLocationsModule']['centralContacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['contacts']`

NCT06713798

  • 2026-03-24 02:11:00 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-06` to `2026-03`
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `statusModule.startDateStruct.date` changed from `2025-07` to `2025-01-30`
    • Field `statusModule.startDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2028-01` to `2025-09-15`
    • Field `statusModule.primaryCompletionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.completionDateStruct.date` changed from `2030-01` to `2025-09-15`
    • Field `statusModule.completionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-06-23` to `2026-03-19`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-06-24` to `2026-03-23`
    • Field `designModule.enrollmentInfo.count` changed from `115` to `0`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • New field added: `root['statusModule']['whyStopped']`
    • Field removed: `root['contactsLocationsModule']`

NCT05294952

  • 2026-03-03 00:59:11 (Trial Update)
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT06754501

  • 2026-02-19 01:00:00 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-08` to `2026-02`
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-10-01` to `2026-02-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-10-07` to `2026-02-18`
    • Field `designModule.enrollmentInfo.count` changed from `35` to `4`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • Field removed: `root['statusModule']['expandedAccessInfo']`
    • Field removed: `root['contactsLocationsModule']['centralContacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['contacts']`

NCT05805501

  • 2026-02-16 21:08:09 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-02`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-07-31` to `2026-10-31`
    • Field `statusModule.completionDateStruct.date` changed from `2026-07-31` to `2026-10-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-12` to `2026-02-10`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-13` to `2026-02-12`

NCT05009069

  • 2026-02-28 00:50:46 (Trial Update)
    • New field added: `root['referencesModule']`

NCT05414032

  • 2026-02-26 00:55:49 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-03` to `2026-02`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-07` to `2027-09`
    • Field `statusModule.completionDateStruct.date` changed from `2026-07` to `2028-07`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-03-25` to `2026-02-23`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-03-30` to `2026-02-25`
    • Field `descriptionModule.briefSummary` changed from `This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 200 patients are expected to be enrolled.` to `This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 100 patients are expected to be enrolled.`
    • Field `descriptionModule.detailedDescription` changed from `This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 200 patients are expected to be enrolled.
    • The study is divided in 5 parts:
    • Part A and Part B are common for all patients in the study, which are defined as the periods of definitive treatment and post definitive treatment. Definitive treatment will be either surgery followed by radiation or chemoradiation; definitive radiation or definitive chemoradiation according to standard of care (SOC) in our institution. A baseline ctDNA sample collection and CT staging will be done before treatment. ctDNA analysis will be performed in Part B at approximately week 5 and at week 10 of this period, and patients will be classified as MRD positive or MRD negative based on the week 10 results. If a patient has equivocal results, a new sample will be taken around week 14. Patients who receive surgery as part of their treatment, will also get ctDNA analysis post-surgery.
    • Part C is the randomized and interventional part of the study (n=60) for patients with MRD. The patient will be randomized 3:1 to Arm A (treatment with AZD2936) or Arm B (observation). Patients in Arm A will continue treatment until the occurrence of any of these circumstances: after completion of 6 cycles, intolerable toxicity or patient decision. ctDNA analysis will be done at week 10 of Part C.
    • Part D is the follow up part for patients with MRD. Two ctDNA samples will be analyzed at week 2 and at week 10 of Part D. Plasma samples will be collected every 6 months for the first 3 years and a final sample will be also collected if the patient has radiological or clinical progression. A CT/MRI scan will be performed at week 2 of Part D and, if clinically needed, according to SOC.
    • Part E is the observational follow up part for patients without MRD. A ctDNA sample will be collected at the time of the first follow up and at radiological or clinical progression if applicable.` to `This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 100 patients are expected to be enrolled.
    • The study is divided in 5 parts:
    • Part A and Part B are common for all patients in the study, which are defined as the periods of definitive treatment and post definitive treatment. Definitive treatment will be either surgery followed by radiation or chemoradiation; definitive radiation or definitive chemoradiation according to standard of care (SOC) in our institution. A baseline ctDNA sample collection and CT staging will be done before treatment. ctDNA analysis will be performed in Part B at approximately week 5, week 10, week 26 and week 52 of this period, and patients will be classified as MRD positive or MRD negative. Patients who receive surgery as part of their treatment, will also get ctDNA analysis post-surgery.
    • Part C is the interventional part of the study (n=14) for patients with MRD or radiological/clinical progression. Patients will continue treatment until the occurrence of any of these circumstances: after completion of 6 cycles, intolerable toxicity or patient decision. ctDNA analysis will be done at week 10 of Part C.
    • Part D is the follow up part for patients with MRD or radiological/clinical progression. Two ctDNA samples will be analyzed at week 2 and at week 10 of Part D. Plasma samples will be collected every 6 months for the first 3 years and a final sample will be also collected if the patient has radiological or clinical progression. A CT/MRI scan will be performed at week 2 of Part D and, if clinically needed, according to SOC.
    • Part E is the observational follow up part for patients without MRD at the completion of part B or with MRD but fail screening to enter Parts C and D. ctDNA samples will be collected at radiological or clinical progression. Additional plasma samples at 6 and 12 months after completion of part B are strongly recommended.`
    • Field `designModule.enrollmentInfo.count` changed from `200` to `102`
    • Field `armsInterventionsModule.armGroups.[0]label` changed from `MRD positive Cohort - Arm A (treatment)` to `MRD positive and/or radiological/clinical progression Cohort`
    • Field `armsInterventionsModule.interventions.[0]armGroupLabels.[0]` changed from `MRD positive Cohort - Arm A (treatment)` to `MRD positive and/or radiological/clinical progression Cohort`

NCT05568095

  • 2026-04-03 02:29:25 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-02` to `2026-03-31`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-04` to `2026-04-02`
  • 2026-03-05 00:58:08 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-30` to `2026-03-02`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-02` to `2026-03-04`

NCT05327530

  • 2026-04-04 02:21:51 (Trial Update)
    • Field `contactsLocationsModule.locations.[63]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[63]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[63]geoPoint.lon` changed from `11.88586` to `11.14261`
  • 2026-03-21 02:05:09 (Trial Update)
    • Field `contactsLocationsModule.locations.[61]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[61]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[61]geoPoint.lon` changed from `14.5195` to `14.26811`
    • Field `contactsLocationsModule.locations.[62]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[62]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[62]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT04736173

  • 2026-03-31 02:31:36 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-06` to `2026-03-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-09` to `2026-03-30`
  • 2026-03-10 02:06:11 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-09` to `2026-03-06`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-15` to `2026-03-09`
    • Field `contactsLocationsModule.locations.[1]facility` changed from `General hospital of Athens, chest diseases Sotiria` to `Lumi Cancer Institute`
    • Field `contactsLocationsModule.locations.[1]city` changed from `Athens` to `Kingwood`
    • Field `contactsLocationsModule.locations.[1]country` changed from `Greece` to `United States`
    • Field `contactsLocationsModule.locations.[1]geoPoint.lat` changed from `37.98376` to `30.05691`
    • Field `contactsLocationsModule.locations.[1]geoPoint.lon` changed from `23.72784` to `-95.18349`
    • Field `contactsLocationsModule.locations.[0]facility` changed from `Hope and Healing Cancer Service` to `Oncology and Hematology Associates of Southwest Virginia, Inc.`
    • Field `contactsLocationsModule.locations.[0]city` changed from `Hinsdale` to `Blacksburg`
    • Field `contactsLocationsModule.locations.[0]state` changed from `Illinois` to `Virginia`
    • Field `contactsLocationsModule.locations.[0]zip` changed from `60521` to `24014`
    • Field `contactsLocationsModule.locations.[0]geoPoint.lat` changed from `41.80086` to `37.22957`
    • Field `contactsLocationsModule.locations.[0]geoPoint.lon` changed from `-87.93701` to `-80.41394`
    • Field `contactsLocationsModule.locations.[23]facility` changed from `Metro Davao Medical and Research Centre` to `Metro Davao Medical And Research Center Inc.`
    • Field `contactsLocationsModule.locations.[24]facility` changed from `Makati Medical Centre` to `St Luke's Medical Center`
    • Field `contactsLocationsModule.locations.[36]facility` changed from `Keimyung University Dongsan Hospital` to `Keimyung University`
    • Field `contactsLocationsModule.locations.[87]facility` changed from `Kocaeli Universitiesi Tip Fakultesi` to `Goztepe Prof. Dr. Suleyman Yalcin City Hospital`
    • New field added: `root['contactsLocationsModule']['locations'][1]['state']`
    • New field added: `root['contactsLocationsModule']['locations'][1]['zip']`

NCT07115043

  • 2026-03-18 02:24:04 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-04` to `2026-03-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-05` to `2026-03-17`
    • Field `contactsLocationsModule.locations.[2]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[5]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-02-10 07:03:45 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-18` to `2026-02-04`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-19` to `2026-02-05`
    • Field `contactsLocationsModule.locations.[1]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[3]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT03739710

  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[25]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[25]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[25]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT06334406

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT05123482

  • 2026-03-24 02:11:01 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-11` to `2026-03-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-13` to `2026-03-23`
    • Field `contactsLocationsModule.locations.[26]status` changed from `SUSPENDED` to `TERMINATED`
  • 2026-02-16 21:08:10 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-02` to `2026-02-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-08` to `2026-02-13`
    • Field `contactsLocationsModule.locations.[0]status` changed from `RECRUITING` to `COMPLETED`
    • Field `contactsLocationsModule.locations.[1]status` changed from `RECRUITING` to `COMPLETED`
    • Field `contactsLocationsModule.locations.[18]status` changed from `WITHDRAWN` to `NOT_YET_RECRUITING`
    • Field `contactsLocationsModule.locations.[18]city` changed from `South Brisbane` to `Taichung`
    • Field `contactsLocationsModule.locations.[18]zip` changed from `4101` to `40705`
    • Field `contactsLocationsModule.locations.[18]country` changed from `Australia` to `Taiwan`
    • Field `contactsLocationsModule.locations.[18]geoPoint.lat` changed from `-27.48034` to `24.1469`
    • Field `contactsLocationsModule.locations.[18]geoPoint.lon` changed from `153.02049` to `120.6839`

NCT07161414

  • 2026-04-10 02:39:09 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-16` to `2026-04-08`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-17` to `2026-04-09`
  • 2026-03-18 02:24:04 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-20` to `2026-03-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-23` to `2026-03-17`
    • Field `contactsLocationsModule.locations.[6]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[7]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[8]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-02-24 00:57:05 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-18` to `2026-02-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-24` to `2026-02-23`
    • Field `contactsLocationsModule.locations.[8]status` changed from `NOT_YET_RECRUITING` to `SUSPENDED`
    • Field `contactsLocationsModule.locations.[9]status` changed from `NOT_YET_RECRUITING` to `SUSPENDED`

NCT05702229

  • 2026-03-19 02:24:59 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-07-03` to `2027-11-30`
    • Field `statusModule.completionDateStruct.date` changed from `2027-09-28` to `2029-05-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-14` to `2026-03-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-17` to `2026-03-18`
    • Field `descriptionModule.detailedDescription` changed from `Approximately 240 participants will be assigned across 6 substudies, with approximately 40 evaluable participants of the confirmed recommend dose by SRC for study intervention in each corresponding substudy.` to `Approximately 360 participants will be assigned across 4 substudies, with approximately 60 evaluable participants of the confirmed recommend dose by SRC for study intervention in each corresponding substudy/cohort.`
    • Field `designModule.enrollmentInfo.count` changed from `240` to `163`
    • Field `armsInterventionsModule.armGroups.[3]label` changed from `Substudy 4` to `Substudy 4, Cohort 4a1`
    • Field `armsInterventionsModule.armGroups.[3]description` changed from `AZD0901 plus rilvegostomig and 5-fluorouracil or capecitabine` to `Sonesitatug vedotin (AZD0901) plus rilvegostomig and 5-fluorouracil or capecitabine`
    • Field `armsInterventionsModule.armGroups.[5]label` changed from `Substudy 6` to `Substudy 4, Cohort 4a2`
    • Field `armsInterventionsModule.armGroups.[5]description` changed from `AZD0901 plus AZD7789 and 5-fluorouracil or capecitabine` to `Sonesitatug vedotin (AZD0901) plus rilvegostomig and 5-fluorouracil`
    • Field `armsInterventionsModule.armGroups.[4]label` changed from `Substudy 5` to `Substudy 4, Cohort 4b`
    • Field `armsInterventionsModule.armGroups.[4]description` changed from `AZD7789 plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)` to `Sonesitatug vedotin (AZD0901) plus capecitabine`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      • 18 years or older at the time of signing the ICF.
      • Body weight \> 35 kg.
      • Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
      • Has measurable target disease assessed by the Investigator based on RECIST 1.1.
      • ECOG PS zero or one.
      • Life expectancy of at least 12 weeks.
      • Adequate organ and bone marrow function.
      • Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy 4 or Substudy 6 is open for recruitment.
    • Exclusion Criteria:
      • Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by in situhybridisation) or indeterminate gastric or GEJ carcinoma.
      • Untreated or progressive CNS metastatic disease, any leptomeningeal disease, or cord compression.
      • Participants with ascites which cannot be controlled with appropriate interventions.
      • Active infectious diseases, including tuberculosis, HIV infection, or hepatitis A/B/C.
      • Uncontrolled intercurrent illness.
      • Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment.
      • History of another primary malignancy.
      • Previous treatment with an immune-oncology agent.
      • Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4, or Substudy 6 is open for recruitment).` to `Inclusion Criteria:
      • 18 years or older at the time of signing the ICF.
      • Body weight \> 35 kg.
      • Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
      • Has measurable target disease assessed by the Investigator based on RECIST 1.1.
      • ECOG PS zero or one.
      • Life expectancy of at least 12 weeks.
      • Adequate organ and bone marrow function.
      • Has central lab confirmed Claudin18.2 status at screening from archival tumour collected within past 24 months or from a fresh biopsy when Substudy 3, Substudy 4 i s open for recruitment.
    • Exclusion Criteria:
      • Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by in situhybridisation) or indeterminate gastric or GEJ carcinoma.
      • Untreated or progressive CNS metastatic disease, any leptomeningeal disease, or cord compression.
      • Participants with ascites which cannot be controlled with appropriate interventions.
      • Active infectious diseases, including tuberculosis, HIV infection, or hepatitis B/C.
      • Uncontrolled intercurrent illness.
      • Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment.
      • History of another primary malignancy.
      • Previous treatment with an immune-oncology agent.
      • Previous treatment with any modalities of Claudin18.2 target therapy or MMAE exposure (when Substudy 3, Substudy 4 is open for recruitment).`
    • Field `armsInterventionsModule.interventions.[0]` changed from `{'type': 'DRUG', 'name': 'Rilvegostomig', 'description': 'an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion', 'armGroupLabels': ['Substudy 2', 'Substudy 4']}` to `{'type': 'DRUG', 'name': 'Rilvegostomig', 'description': 'an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion', 'armGroupLabels': ['Substudy 2', 'Substudy 4, Cohort 4a1', 'Substudy 4, Cohort 4a2']}`
    • Field `armsInterventionsModule.interventions.[2]` changed from `{'type': 'DRUG', 'name': 'FOLFOX', 'description': '5-fluorouracil 400 mg/m\\^2 IV, oxaliplatin 85 mg/m\\^2, leucovorin 400 mg/m\\^2 (or levoleucovorin 200 mg/m\\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\\^2 IV 24 h day 1-2', 'armGroupLabels': ['Substudy 1', 'Substudy 2', 'Substudy 5']}` to `{'type': 'DRUG', 'name': 'FOLFOX', 'description': '5-fluorouracil oxaliplatin, leucovorin (levoleucovorin when locally preferred and available)', 'armGroupLabels': ['Substudy 1', 'Substudy 2']}`
    • Field `armsInterventionsModule.interventions.[6]` changed from `{'type': 'DRUG', 'name': '5-Fluorouracil', 'description': '5-FU, IV infusion, Q3W', 'armGroupLabels': ['Substudy 3', 'Substudy 4', 'Substudy 6']}` to `{'type': 'DRUG', 'name': 'Capecitabine', 'description': 'Oral take', 'armGroupLabels': ['Substudy 3', 'Substudy 4, Cohort 4a1', 'Substudy 4, Cohort 4b']}`
    • Field `armsInterventionsModule.armGroups.[4]interventionNames.[1]` changed from `Drug: XELOX` to `Drug: Capecitabine`
    • Field `armsInterventionsModule.interventions.[5]` changed from `{'type': 'DRUG', 'name': 'AZD0901', 'description': 'an anti Claudin18.2 ADC; IV infusion', 'armGroupLabels': ['Substudy 3', 'Substudy 4', 'Substudy 6']}` to `{'type': 'DRUG', 'name': '5-Fluorouracil', 'description': '5-FU, IV infusion', 'armGroupLabels': ['Substudy 3', 'Substudy 4, Cohort 4a1', 'Substudy 4, Cohort 4a2']}`
    • Field `armsInterventionsModule.armGroups.[5]interventionNames.[0]` changed from `Drug: AZD7789` to `Drug: Rilvegostomig`
    • Field `armsInterventionsModule.armGroups.[4]interventionNames.[0]` changed from `Drug: FOLFOX` to `Drug: AZD0901`
    • Field `armsInterventionsModule.interventions.[4]` changed from `{'type': 'DRUG', 'name': 'AZD7789', 'description': 'an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion', 'armGroupLabels': ['Substudy 5', 'Substudy 6']}` to `{'type': 'DRUG', 'name': 'AZD0901', 'description': 'an anti Claudin18.2 ADC; IV infusion', 'armGroupLabels': ['Substudy 3', 'Substudy 4, Cohort 4a1', 'Substudy 4, Cohort 4a2', 'Substudy 4, Cohort 4b']}`
    • Field `armsInterventionsModule.interventions.[3]` changed from `{'type': 'DRUG', 'name': 'XELOX', 'description': 'capecitabine 1000 mg/m\\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\\^2, day 1', 'armGroupLabels': ['Substudy 1', 'Substudy 2', 'Substudy 5']}` to `{'type': 'DRUG', 'name': 'XELOX', 'description': 'capecitabine and oxaliplatin', 'armGroupLabels': ['Substudy 1', 'Substudy 2']}`

NCT05775159

  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[33]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[33]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[33]geoPoint.lon` changed from `14.5195` to `14.26811`
  • 2026-02-19 01:00:01 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-12` to `2026-02-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-13` to `2026-02-18`

NCT05574335

  • 2026-02-12 14:01:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-05` to `2026-02-10`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-06` to `2026-02-11`

NCT06302556

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[2]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[2]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[2]geoPoint.lon` changed from `11.88586` to `11.14261`
  • 2026-03-03 00:59:12 (Trial Update)
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `UNKNOWN`
    • New field added: `root['statusModule']['lastKnownStatus']`

NCT05645692

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[30]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[30]geoPoint.lat` changed from `45.40797` to `45.26618`
    • Field `contactsLocationsModule.locations.[30]geoPoint.lon` changed from `11.88586` to `11.77208`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[24]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[24]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[24]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT06346197

  • 2026-04-09 02:28:32 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-23` to `2026-04-02`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-25` to `2026-04-08`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      • Male or female patient ≥18 years of age at time of informed consent form signature.
      • Patient with MSI-H/dMMR, HER2 negativeadvanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5.
      • Patient to be treated with a first line therapy for locally advanced/metastatic disease.
      • No prior treatment with chemotherapy for locally advanced/metastatic disease.
    • o Note - adjuvant or neoadjuvant chemotherapy is allowed providing that 6 months have relapsed between completion of adjuvant chemotherapy and recurrence.
      • Measurable disease (outside any previous irradiated field within the past 6 months) defined as at least one unidimensional lesion that can be accurately measured as ≥ 10 mm with CT scan according to RECIST V1.1 (Appendix 01).
      • Note: Lesions intended to be biopsied should not be defined as target lesions.
      • Note: previously irradiated lesions can be selected as target lesion only if recurrence/PD is documented after RT.
      • Patient with PS ECOG 0 or 1 (Appendix 02).
      • Adequate hematologic and end-organ function, defined by the following laboratory test results:
    • Absolute neutrophil count ≥ 1.5 109/L (without growth factor support within 14 d) Platelets ≥ 100 109/L (without transfusion for platelets within 7 d) Hemoglobin ≥ 9 g/dL (without transfusion within 7 d) Creatinine clearance according to CKD-EPI ≥ 30 mL/min/1.73 m2 Serum total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert disease for whom a total serum bilirubin ≤ 3 x ULN is acceptable) ASAT and ALAT ≤ 3 x ULN (or up to 5 x ULN in case of liver metastasis or hepatic infiltration)
      • Availability of a representative formalin-fixed paraffin-embedded (FFPE) sample of the primary or metastatic tumor tissue (resection or biopsy) with an associated pathology report must be available. This tumor sample must meet the following quality/quantity control criteria: ≥30 % of tumor cells and a tumor surface area ≥ 5mm2 or biopsiable disease (see next inclusion criteria).
      • Tumor lesion visible by medical imaging and accessible to repeatable percutaneous or endoscopic sampling that permits core needle biopsy without unacceptable risk of a significant procedural complications, and suitable for retrieval of a minimum of 4 cores with a needle minimum diameter :16-gauge.
      • Note 1: Fine needle aspirates, bone biopsies do not satisfy the requirement for tumor tissue.
      • Note 2: Tumor lesions used for biopsy should not be lesions used as RECIST 1.1 target lesions unless there are no other lesions suitable for biopsy. If a RECIST target lesion is used for biopsy, the lesion must be ≥ 2 cm in longest diameter.
      • Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at the Screening Visit (within 72 hours of first dose of study drugs) and must agree to use highly effective contraceptive measures starting with the Screening Visit through
      • 9 months after the end of the treatment with oxaliplatin
      • 6 months after the end of the treatment with fluorouracil
      • 5 months after the end of the treatment with nivolumab or botensilimab or Balstilimab
      • 6 months for capecitabine
      • Highly effective contraception is defined in Appendix 03.
    • Note Non-childbearing potential is defined as:
      1. ≥ 50 years of age and has not had menses for greater than 1 year.
      1. Amenorrheic for ≥ 2 years without a hysterectomy and bilateral oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation.
      1. Status is post-hysterectomy, bilateral oophorectomy, or tubal ligation.
      • Male patients with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study starting with the screening visit through 6 months after the end of the treatment with oxaliplatine or 3 months after the last dose for other study treatments is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.
      • Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed and should be able and willing to comply with study visits and procedures as per protocol.
      • Patients must be covered by a medical insurance.
    • Exclusion Criteria:
      • Oesogastric cancer eligible to treatment with curative intent
      • Patients previously treated by anti-PD-1, anti-PD-L1, or anti-CTLA-4 or any other immunotherapy
      • Patients with surgery or radiotherapy within less than 4 weeks before C1D1
      • Patients with persistent AE Grade \>1 related to previous anti-cancer treatment, except alopecia (all grades), laboratory value according to criteria I7.
      • Patients with: hypokalemia, hypomagnesemia, hypocalcemia less than normal
      • Patients with known prolongation QT/QTc interval i.e. QT/QTc interval longer than 450 msec for men and longer than 470 msec for women according to the inclusion ECG.
      • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
    • Note: Asymptomatic patients with treated CNS lesions are eligible, provided that all of the following criteria are met:
      • Measurable disease, per RECIST v1.1, must be present outside the CNS.
      • The patient has no history of intracranial hemorrhage or spinal cord hemorrhage.
      • Metastases are limited to the cerebellum or the supratentorial region (i.e., no metastases to the midbrain, pons, medulla, or spinal cord).
      • There is no evidence of interim progression between completion of CNS-directed therapy and initiation of study treatment.
      • The patient has not undergone stereotactic radiotherapy within 7 days prior to initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, neurosurgical resection within 21 days prior to initiation of study treatment.
      • The patient has no ongoing requirement for corticosteroids as therapy for CNS disease. Anticonvulsant therapy at a stable dose is permitted. A minimal wash-out period of 10days for corticosteroids is required.
      • Patients with other malignancy unless this malignancy is not expected to interfere with the evaluation of study endpoints (basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, localized prostate cancer), or with no evidence of disease for ≥ 2 years.
      • Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
      • of ILD or non-infectious pneumonitis requiring glucocorticoids.
      • History of allogeneic organ transplant.
      • Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
      • Patient with peripheral sensory neuropathy with functional impairment.
      • Patients with clinically significant active heart disease or myocardial infarction within 6 months, history of uncontrolled or symptomatic cardiac disease.
      • Patient with recent (within 7d before C1D1) or concomitant treatment with brivudine.
      • Patient with complete absence of dihydropyrimidine dehydrogenase (DPD) activity (blood uracil level ≥ 150 ng/mL) or partial deficit in DPD (i.e. blood uracil level between ≥ 16 ng/ml and \< 150 ng/mL)
      • Patients with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent) are permitted in the absence of active autoimmune disease.
      • Patient with Live vaccines injection within 4 weeks before C1D1. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever and BCG. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed.
      • Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (i.e., with use of disease-modifying agents or immunosuppressive drugs).
      • History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
      • Patients with documented:
      • Active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \[HBsAg\] test at screening) unless their HBV is stably controlled on nucleoside analogs (eg entecavir or tenofovir) which will be continued for the duration of the study. Note: Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to C1D1.
      • Active hepatitis C. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA, or
      • HIV infection
      • Prior organ or bone marrow transplant.
      • Pregnant or lactating women.` to `Inclusion Criteria:
      • Male or female patient ≥18 years of age at time of informed consent form signature.
      • Patient with MSI-H/dMMR, HER2 negativeadvanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥ 5. Note :The claudin 18.2 status must be known and documented before inclusion.
      • Patient to be treated with a first line therapy for locally advanced/metastatic disease.
      • No prior treatment with chemotherapy for locally advanced/metastatic disease.
    • o Note - adjuvant or neoadjuvant chemotherapy is allowed providing that 6 months have relapsed between completion of adjuvant chemotherapy and recurrence.
      • Measurable disease (outside any previous irradiated field within the past 6 months) defined as at least one unidimensional lesion that can be accurately measured as ≥ 10 mm with CT scan according to RECIST V1.1 (Appendix 01).
      • Note: Lesions intended to be biopsied should not be defined as target lesions.
      • Note: previously irradiated lesions can be selected as target lesion only if recurrence/PD is documented after RT.
      • Patient with PS ECOG 0 or 1 (Appendix 02).
      • Adequate hematologic and end-organ function, defined by the following laboratory test results:
    • Absolute neutrophil count ≥ 1.5 109/L (without growth factor support within 14 d) Platelets ≥ 100 109/L (without transfusion for platelets within 7 d) Hemoglobin ≥ 9 g/dL (without transfusion within 7 d) Creatinine clearance according to CKD-EPI ≥ 30 mL/min/1.73 m2 Serum total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert disease for whom a total serum bilirubin ≤ 3 x ULN is acceptable) ASAT and ALAT ≤ 3 x ULN (or up to 5 x ULN in case of liver metastasis or hepatic infiltration)
      • Availability of a representative formalin-fixed paraffin-embedded (FFPE) sample of the primary or metastatic tumor tissue (resection or biopsy) with an associated pathology report must be available. This tumor sample must meet the following quality/quantity control criteria: ≥30 % of tumor cells and a tumor surface area ≥ 5mm2 or biopsiable disease (see next inclusion criteria).
      • Tumor lesion visible by medical imaging and accessible to repeatable percutaneous or endoscopic sampling that permits core needle biopsy without unacceptable risk of a significant procedural complications, and suitable for retrieval of a minimum of 4 cores with a needle minimum diameter :16-gauge.
      • Note 1: Fine needle aspirates, bone biopsies do not satisfy the requirement for tumor tissue.
      • Note 2: Tumor lesions used for biopsy should not be lesions used as RECIST 1.1 target lesions unless there are no other lesions suitable for biopsy. If a RECIST target lesion is used for biopsy, the lesion must be ≥ 2 cm in longest diameter.
      • Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at the Screening Visit (within 72 hours of first dose of study drugs) and must agree to use highly effective contraceptive measures starting with the Screening Visit through
      • 9 months after the end of the treatment with oxaliplatin
      • 6 months after the end of the treatment with fluorouracil
      • 5 months after the end of the treatment with nivolumab or botensilimab or Balstilimab
      • 6 months for capecitabine
      • Highly effective contraception is defined in Appendix 03.
    • Note Non-childbearing potential is defined as:
      1. ≥ 50 years of age and has not had menses for greater than 1 year.
      1. Amenorrheic for ≥ 2 years without a hysterectomy and bilateral oophorectomy and a follicle-stimulating hormone value in the postmenopausal range upon pre-study (screening) evaluation.
      1. Status is post-hysterectomy, bilateral oophorectomy, or tubal ligation.
      • Male patients with a female partner(s) of childbearing potential must agree to use highly effective contraceptive measures throughout the study starting with the screening visit through 6 months after the end of the treatment with oxaliplatine or 3 months after the last dose for other study treatments is received. Males with pregnant partners must agree to use a condom; no additional method of contraception is required for the pregnant partner.
      • Patient should understand, sign, and date the written voluntary informed consent form prior to any protocol-specific procedures performed and should be able and willing to comply with study visits and procedures as per protocol.
      • Patients must be covered by a medical insurance.
    • Exclusion Criteria:
      • Oesogastric cancer eligible to treatment with curative intent
      • Patients previously treated by anti-PD-1, anti-PD-L1, or anti-CTLA-4 or any other immunotherapy
      • Patients with surgery or radiotherapy within less than 4 weeks before C1D1
      • Patients with persistent AE Grade \>1 related to previous anti-cancer treatment, except alopecia (all grades), laboratory value according to criteria I7.
      • Patients with: hypokalemia, hypomagnesemia, hypocalcemia less than normal
      • Patients with known prolongation QT/QTc interval i.e. QT/QTc interval longer than 450 msec for men and longer than 470 msec for women according to the inclusion ECG.
      • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
    • Note: Asymptomatic patients with treated CNS lesions are eligible, provided that all of the following criteria are met:
      • Measurable disease, per RECIST v1.1, must be present outside the CNS.
      • The patient has no history of intracranial hemorrhage or spinal cord hemorrhage.
      • Metastases are limited to the cerebellum or the supratentorial region (i.e., no metastases to the midbrain, pons, medulla, or spinal cord).
      • There is no evidence of interim progression between completion of CNS-directed therapy and initiation of study treatment.
      • The patient has not undergone stereotactic radiotherapy within 7 days prior to initiation of study treatment, whole-brain radiotherapy within 14 days prior to initiation of study treatment, neurosurgical resection within 21 days prior to initiation of study treatment.
      • The patient has no ongoing requirement for corticosteroids as therapy for CNS disease. Anticonvulsant therapy at a stable dose is permitted. A minimal wash-out period of 10days for corticosteroids is required.
      • Patients with other malignancy unless this malignancy is not expected to interfere with the evaluation of study endpoints (basal or squamous cell carcinoma of the skin, in-situ carcinoma of the cervix, localized prostate cancer), or with no evidence of disease for ≥ 2 years.
      • Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.
      • of ILD or non-infectious pneumonitis requiring glucocorticoids.
      • History of allogeneic organ transplant.
      • Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
      • Patient with peripheral sensory neuropathy with functional impairment.
      • Patients with clinically significant active heart disease or myocardial infarction within 6 months, history of uncontrolled or symptomatic cardiac disease.
      • Patient with recent (within 7d before C1D1) or concomitant treatment with brivudine.
      • Patient with complete absence of dihydropyrimidine dehydrogenase (DPD) activity (blood uracil level ≥ 150 ng/mL) or partial deficit in DPD (i.e. blood uracil level between ≥ 16 ng/ml and \< 150 ng/mL)
      • Patients with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) within 14 days or another immunosuppressive medication within 30 days of the first dose of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses (≤ 10 mg daily prednisone equivalent) are permitted in the absence of active autoimmune disease.
      • Patient with Live vaccines injection within 4 weeks before C1D1. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever and BCG. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed.
      • Active autoimmune disease or history of autoimmune disease that required systemic treatment within 2 years of the start of study treatment (i.e., with use of disease-modifying agents or immunosuppressive drugs).
      • History or current evidence of any condition, co-morbidity, therapy, any active infections, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator.
      • Patients with documented:
      • Active hepatitis B (chronic or acute; defined as having a positive hepatitis B surface antigen \[HBsAg\] test at screening) unless their HBV is stably controlled on nucleoside analogs (eg entecavir or tenofovir) which will be continued for the duration of the study. Note: Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody \[anti-HBc\] and absence of HBsAg) are eligible. HBV DNA test must be performed in these patients prior to C1D1.
      • Active hepatitis C. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA, or
      • HIV infection
      • Prior organ or bone marrow transplant.
      • Pregnant or lactating women.`
    • Field `contactsLocationsModule.locations.[0]contacts.[0]email` changed from `chloe.verner2@gmail.com` to `chloe.vernet2@gmail.com`
    • New field added: `root['contactsLocationsModule']['locations'][1]['zip']`
    • New field added: `root['contactsLocationsModule']['locations'][2]['zip']`
  • 2026-03-26 02:29:47 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-27` to `2026-03-23`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-02` to `2026-03-25`
  • 2026-03-03 00:59:13 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-19` to `2026-02-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-26` to `2026-03-02`

NCT07098338

  • 2026-02-10 07:03:50 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-09` to `2026-01`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2027-03-21` to `2029-04-06`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-09-25` to `2026-02-03`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-09-30` to `2026-02-05`
    • Field `descriptionModule.detailedDescription` changed from `The master protocol will include 3 sub-studies, each focused on a specific disease population.
      • Sub-study 1 will investigate rilvegostomig± ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 ≥50%.
      • Sub-study 2 will investigate rilvegostomig + ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 1-49%.
      • Sub-study 3 will investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+
    • Each sub-study may include 2 parts (unless stated in the individual sub study protocols): Part A: one or more Safety Run-in cohort(s), and Part B: one or more Dose Expansion cohort(s).` to `The master protocol will include 3 sub-studies, each focused on a specific disease population.
      • Sub-study 1 will investigate rilvegostomig± ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 ≥50%.
      • Sub-study 2 will investigate rilvegostomig + ramucirumab in 1L non-actionable genomic alterations (AGA) NSCLC with PD-L1 1-49%.
      • Sub-study 3 will investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+
    • Each sub-study may include 2 parts (unless stated in the individual sub study protocols): Part A: one or more Safety Run-in cohort(s), and Part B: one or more Dose Expansion cohort(s).`
    • Field `outcomesModule.primaryOutcomes.[1]description` changed from `ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response), determined by the Investigator at local site per RECIST 1.1` to `ORR is defined as the proportion of participants who have a confirmed CR (complete response) or confirmed PR (partial response) per RECIST 1.1`
    • Field `outcomesModule.secondaryOutcomes.[2]description` changed from `PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) per RECIST 1.1 as assessed by Investigator.` to `PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression) per RECIST 1.1.`
    • Field `contactsLocationsModule.locations.[10]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[11]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[12]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[14]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[16]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[17]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[19]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[26]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[28]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[29]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[32]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[33]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[34]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[36]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[37]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[38]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[40]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[41]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[42]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[43]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[44]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[46]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[48]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[50]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[51]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `armsInterventionsModule.armGroups.[0]` changed from `{'label': 'Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig ± ramucirumab until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}` to `{'label': 'Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig ± ramucirumab until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}`
    • Field `armsInterventionsModule.interventions.[2]` changed from `{'type': 'DRUG', 'name': 'Dato-DXd', 'description': 'Dato-DXd will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC'], 'otherNames': ['DS-1062']}` to `{'type': 'DRUG', 'name': 'Dato-DXd', 'description': 'Dato-DXd will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC'], 'otherNames': ['DS-1062']}`
    • Field `armsInterventionsModule.interventions.[0]` changed from `{'type': 'DRUG', 'name': 'Rilvegostomig', 'description': 'Rilvegostomig will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC'], 'otherNames': ['AZD2936']}` to `{'type': 'DRUG', 'name': 'Rilvegostomig', 'description': 'Rilvegostomig will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC'], 'otherNames': ['AZD2936']}`
    • Field `armsInterventionsModule.armGroups.[2]` changed from `{'label': 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Dato-DXd + ramucirumab ± rilvegostomig until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab', 'Drug: Dato-DXd']}` to `{'label': 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive Dato-DXd + ramucirumab ± rilvegostomig until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab', 'Drug: Dato-DXd']}`
    • Field `armsInterventionsModule.armGroups.[1]` changed from `{'label': 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig + ramucirumab until RECIST 1.1-defined radiological progression as assessed by the investigator, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}` to `{'label': 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'type': 'EXPERIMENTAL', 'description': 'Participants will receive rilvegostomig + ramucirumab until RECIST 1.1-defined radiological progression, unacceptable toxicity, withdrawal of consent, or other discontinuation criterion', 'interventionNames': ['Drug: Rilvegostomig', 'Drug: Ramucirumab']}`
    • Field `armsInterventionsModule.interventions.[1]` changed from `{'type': 'DRUG', 'name': 'Ramucirumab', 'description': 'Ramucirumab will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2L AGA+ NSCLC'], 'otherNames': ['Cyramza']}` to `{'type': 'DRUG', 'name': 'Ramucirumab', 'description': 'Ramucirumab will be administered as IV infusion.', 'armGroupLabels': ['Sub-study 1, investigate rilvegostomig± ramucirumab in 1L non-AGA NSCLC with PD-L1 ≥50%', 'Sub-study 2, investigate rilvegostomig + ramucirumab in 1L non-AGA NSCLC with PD-L1 1-49%', 'Sub-study 3, investigate Dato-DXd + ramucirumab ± rilvegostomig in 2/3L AGA+ NSCLC'], 'otherNames': ['Cyramza']}`

NCT05329766

  • 2026-03-31 02:31:37 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-25` to `2026-03-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-27` to `2026-03-30`
  • 2026-02-28 00:50:47 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-27` to `2026-02-25`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-29` to `2026-02-27`

NCT07221253

  • 2026-03-18 02:24:04 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-09` to `2026-03-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-10` to `2026-03-17`
    • Field `contactsLocationsModule.locations.[3]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[14]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[23]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[32]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[42]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[45]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[50]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[51]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[57]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[61]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[64]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[66]zip` changed from `471003` to `471023`
    • Field `contactsLocationsModule.locations.[108]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[109]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[113]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[114]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[115]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[116]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[126]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[129]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[141]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[144]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[151]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-02-12 14:01:40 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-07` to `2026-02-09`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-08` to `2026-02-10`
    • Field `contactsLocationsModule.locations.[32]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[39]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[40]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[43]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[58]status` changed from `NOT_YET_RECRUITING` to `SUSPENDED`
    • Field `contactsLocationsModule.locations.[89]city` changed from `Lichtenberg` to `Berlin`
    • Field `contactsLocationsModule.locations.[89]geoPoint.lat` changed from `52.51395` to `52.52437`
    • Field `contactsLocationsModule.locations.[89]geoPoint.lon` changed from `13.49975` to `13.41053`
    • Field `contactsLocationsModule.locations.[103]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[131]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[138]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[141]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[143]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[145]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[147]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT05676931

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[24]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[24]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[24]geoPoint.lon` changed from `11.88586` to `11.14261`

NCT04543617

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[79]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[79]geoPoint.lat` changed from `45.40797` to `45.26618`
    • Field `contactsLocationsModule.locations.[79]geoPoint.lon` changed from `11.88586` to `11.77208`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[76]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[76]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[76]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT04305041

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[30]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[30]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[30]geoPoint.lon` changed from `11.88586` to `11.14261`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[29]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[29]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[29]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT06996782

  • 2026-03-31 02:31:37 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-23` to `2026-03-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-24` to `2026-03-30`
    • Field `contactsLocationsModule.locations.[46]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[55]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[56]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[58]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[60]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[62]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[82]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[97]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-02-25 01:02:25 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-13` to `2026-02-23`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-14` to `2026-02-24`
    • Field `contactsLocationsModule.locations.[7]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[8]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[47]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[79]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT05665595

  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[142]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[142]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[142]geoPoint.lon` changed from `14.5195` to `14.26811`
  • 2026-03-18 02:24:04 (Trial Update)
    • Field `referencesModule.references.[0]citation` changed from `Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen J, Rivalland G, Coetzee C, Ribas A, Mujika K, Markel G, Villarroel RU, Dizdar O, Caglevic C, Grebennik D, Donovan K, Krepler C, Long GV. Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study. Lancet Oncol. 2026 Feb 13:S1470-2045(25)00709-0. doi: 10.1016/S1470-2045(25)00709-0. Online ahead of print.` to `Dummer R, Guo J, Luke JJ, Carlino MS, Schadendorf D, Khattak MA, Hauschild A, Ascierto PA, Chen Y, Shin SJ, Rutkowski P, Luo Z, Chen J, Rivalland G, Coetzee C, Ribas A, Mujika K, Markel G, Villarroel RU, Dizdar O, Caglevic C, Grebennik D, Donovan K, Krepler C, Long GV. Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study. Lancet Oncol. 2026 Mar;27(3):327-339. doi: 10.1016/S1470-2045(25)00709-0. Epub 2026 Feb 13.`
  • 2026-02-19 01:00:02 (Trial Update)
    • Minor formatting updates.

NCT06868277

  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[197]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[197]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[197]geoPoint.lon` changed from `14.5195` to `14.26811`
  • 2026-03-03 00:59:14 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-12` to `2026-02-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-13` to `2026-03-02`
    • Field `contactsLocationsModule.locations.[28]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[29]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[31]zip` changed from `2000` to `S2000CVB`
    • Field `contactsLocationsModule.locations.[42]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[49]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[50]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[52]city` changed from `Santo André` to `São Paulo`
    • Field `contactsLocationsModule.locations.[52]zip` changed from `09060-650` to `03102-006`
    • Field `contactsLocationsModule.locations.[52]geoPoint.lat` changed from `-23.66389` to `-23.5475`
    • Field `contactsLocationsModule.locations.[52]geoPoint.lon` changed from `-46.53833` to `-46.63611`
    • Field `contactsLocationsModule.locations.[54]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[55]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[69]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[122]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[139]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[143]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[148]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[153]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[155]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[157]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[160]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[165]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[224]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[272]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[273]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT06692738

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[202]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[202]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[202]geoPoint.lon` changed from `11.88586` to `11.14261`
  • 2026-04-01 02:42:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-24` to `2026-03-30`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-25` to `2026-03-31`
    • Field `contactsLocationsModule.locations.[0]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[49]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[156]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[227]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[251]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • New field added: `root['contactsLocationsModule']['locations'][274]['zip']`
  • 2026-02-26 00:55:51 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-20` to `2026-02-24`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-21` to `2026-02-25`
    • Field `contactsLocationsModule.locations.[54]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[90]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[156]status` changed from `SUSPENDED` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[162]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[190]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[194]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[195]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[211]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT04256421

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-09` to `2026-03-13`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-28` to `2026-04-03`
    • Field `outcomesModule.primaryOutcomes.[0]measure` changed from `Investigator-Assessed Progression Free Survival (PFS) in the Primary Analysis Set (PAS)` to `Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)`
    • Field `outcomesModule.primaryOutcomes.[0]description` changed from `PFS was defined as the time from randomization to the first documented disease progression (PD) as determined by the investigator with the use of Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurred first. PD: at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of \>/= 5 millimeters (mm).` to `PFS was defined as the time from randomization to the first documented PD as determined by the investigator with the use of Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm).`
    • Field `outcomesModule.primaryOutcomes.[0]timeFrame` changed from `From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 24 months)` to `From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)`
    • Field `contactsLocationsModule.locations.[57]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[57]geoPoint.lat` changed from `45.40797` to `45.26618`
    • Field `contactsLocationsModule.locations.[57]geoPoint.lon` changed from `11.88586` to `11.77208`
    • Field `outcomesModule.secondaryOutcomes.[13]` changed from `{'measure': 'TTCD of EORTC QLQ-C30 GHS/QoL in the FAS', 'description': 'TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in patient-reported global health status (GHS)/ quality of life (QoL). TTCD was determined based on patient-reported GHS/QoL (items 29-30) as collected and measured by the EORTC QLQ-C30. HS/ QoL items are scored on a 7-point scale that ranges from "very poor" to "excellent". A high score for the GHS/QoL subscale represented a high health related quality of life. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in GHS/QoL subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.', 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration up to 24 months'}` to `{'measure': 'TTCD of EORTC QLQ-C30 GHS/QoL in the FAS', 'description': 'TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in patient-reported GHS/QoL. TTCD was determined based on patient-reported GHS/QoL (Items 29-30) as collected and measured by the EORTC QLQ-C30. GHS/QoL items were scored on a 7-point scale, ranging from "very poor" to "excellent". A high score for the GHS/QoL subscale represented a high health-related QoL. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in GHS/QoL subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.', 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[0]` changed from `{'measure': 'PFS in the FAS', 'description': 'PFS was defined as the time from randomization to the first documented PD as determined by the investigator with the use of RECIST v1.1 or death from any cause, whichever occurred first. PD: at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of \\>/= 5 mm.', 'timeFrame': 'From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 24 months)'}` to `{'measure': 'PFS in the FAS', 'description': 'PFS was defined as the time from randomization to the first documented PD as determined by the investigator with the use of RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm.', 'timeFrame': 'From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[6]` changed from `{'measure': 'Investigator-Assessed PFS Rates at 6 Months and 12 Months in the PAS', 'description': 'PFS rate at 6 months and 12 months was defined as the percentage of participants who were event free at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate is a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value is calculated from ordered data (Event, Censoring) of each patient, using the Kaplan-Meier method, and accounts for censored observations( so Event free rates may not directly be calculated based only on patients remaining at risk).', 'timeFrame': 'Month 6, Month 12'}` to `{'measure': 'Investigator-assessed PFS Rates at 6 Months and 12 Months in the PAS', 'description': 'PFS rate at 6 months and 12 months was defined as the percentage of participants who were event-free at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the Kaplan-Meier (K-M) method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).', 'timeFrame': 'Month 6, Month 12'}`
    • Field `outcomesModule.secondaryOutcomes.[16]` changed from `{'measure': 'Cmin of Atezolizumab', 'timeFrame': 'At the end of each cycle (each cycle is 21 days) of Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months)'}` to `{'measure': 'Minimum Serum Concentration (Cmin) of Tiragolumab', 'timeFrame': 'At the end of Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months) (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[10]` changed from `{'measure': 'Time to Confirmed Deterioration (TTCD) of European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core (QLQ-C30) Physical Functioning in the PAS', 'description': "TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in physical functioning. TTCD was determined based on patient-reported physical functioning (items 1-5) as collected and measured by the EORTC QLQ-C30. The PF is measured on 4-point scale (1='Not at all' to 4='Very much'). A high score for the physical function subscale represented a high/healthy level of functioning. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in physical functioning subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.", 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration up to approximately 24 months'}` to `{'measure': 'Time to Confirmed Deterioration (TTCD) of European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-life Questionnaire-Core 30 (QLQ-C30) Physical Functioning (PF) in the PAS', 'description': "TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in PF. TTCD was determined based on patient-reported PF (Items 1-5) as collected and measured by the EORTC QLQ-C30. The PF was measured on 4-point scale (1='Not at all' to 4='Very much'). A high score for the PF subscale represented a high/healthy level of functioning. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in PF subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.", 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[15]` changed from `{'measure': 'Minimum Serum Concentration (Cmin) of Tiragolumab', 'timeFrame': 'At the end of each cycle (each cycle is 21 days) of Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months)'}` to `{'measure': 'Number of Participants With Severity of Cytokine-release Syndrome (CRS), as Determined by the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale', 'description': 'CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms may be progressive, including fever at onset, and may also include hypotension, capillary leak (hypoxia), and end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades: Grade 1: Fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \\& hypoxia; Grade 2: Fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: Fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: Fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive-pressure ventilation; Grade 5: death due to CRS. Only non zero values have been reported.', 'timeFrame': 'Up to 58 months'}`
    • Field `outcomesModule.secondaryOutcomes.[17]` changed from `{'measure': 'Maximum Serum Concentration (Cmax) of Tiragolumab', 'timeFrame': 'Predose and 30 minutes post end of infusion (EOI) on Day 1 of Cycle 1 (each cycle is 21 days)'}` to `{'measure': 'Cmin of Atezolizumab', 'timeFrame': 'At the end of each Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months) (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[19]` changed from `{'measure': 'Number of Participants With Anti-Drug Antibodies (ADAs) to Tiragolumab', 'description': 'Reported here is the number of participants who had a positive ADA assay result at baseline and the number of participants positive for treatment emergent ADAs. The participants positive for treatment emergent ADAs include treatment-induced and treatment-enhanced ADA positive participants. Treatment-induced ADAs are participants with negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADAs are participants with a positive ADA result at baseline who had one or more post-baseline titer results that were at least 0.60 t.u. greater than the baseline titer result. The total number of participants who developed ADAs to tiragolumab was determined by summing the ADA-positive participants across all timepoints.', 'timeFrame': 'Predose on Day 1 of Cycles 1 (each cycle is 21 days), 2, 3, 4, 8,12 and 16 and at treatment discontinuation (TD) visit (up to 24 months)'}` to `{'measure': 'Cmax of Atezolizumab', 'timeFrame': 'Pre-dose and 30 minutes post EOI on Day 1 of Cycle 1 (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[14]` changed from `{'measure': 'Percentage of Participants With Adverse Events', 'description': 'An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.', 'timeFrame': 'Up to 65 months'}` to `{'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study were also considered as AEs.', 'timeFrame': 'Up to 58 months'}`
    • Field `outcomesModule.secondaryOutcomes.[8]` changed from `{'measure': 'Overall Survival Rates at 12 Months and 24 Months in the PAS', 'description': 'Overall survival rate at 12 months and 24 months was defined as the percentage of participants who were alive at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate is a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value is calculated from ordered data (Event, Censoring) of each patient, using the Kaplan-Meier method, and accounts for censored observations( so Event free rates may not directly be calculated based only on patients remaining at risk).', 'timeFrame': 'Month 12, Month 24'}` to `{'measure': 'OS Rates at 12 Months and 24 Months in the PAS', 'description': 'OS rate at 12 months and 24 months was defined as the percentage of participants who were alive at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the K-M method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).', 'timeFrame': 'Month 12, Month 24'}`
    • Field `outcomesModule.secondaryOutcomes.[18]` changed from `{'measure': 'Cmax of Atezolizumab', 'timeFrame': 'Predose and 30 minutes post EOI on Day 1 of Cycle 1 (each cycle is 21 days)'}` to `{'measure': 'Maximum Serum Concentration (Cmax) of Tiragolumab', 'timeFrame': 'Pre-dose and 30 minutes post end of infusion (EOI) on Day 1 of Cycle 1 (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[21]` changed from `{'measure': 'Change From Baseline in EuroQol 5-Dimension, 5-Level (EQ-5D-5L) Index-based and Visual Analog Scale Scores', 'description': "The EQ-5D-5L is a validated self-report health status questionnaire that was used to calculate a health status utility score for use in health economic analyses. There were two components to the EQ-5D-5L: a five-item health state profile that assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, as well as a visual analog scale (VAS) that measured health state. The EQ VAS records the participant's self-rated health on a vertical visual analogue scale ranging from 0 to 100 A single composite score was calculated based on the responses as an indicator of the participant's health status. The scale ranges 0-100, 0=worst health and 100=best health.", 'timeFrame': 'From baseline up to 65 months'}` to `{'measure': 'Number of Participants With ADAs to Atezolizumab', 'description': 'Participants were considered to be ADA-positive if they were ADA-negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). The total number of participants who developed ADAs to tiragolumab was determined by summing the ADA-positive participants across all timepoints.', 'timeFrame': 'Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8,12, 16 and at TD visit (up to 24 months) (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[5]` changed from `{'measure': 'Investigator-Assessed DOR in the FAS', 'description': 'DOR was defined as the time from the first occurrence of a documented OR to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR: was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \\< 10 mm PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD= at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of \\>/= 5 mm.', 'timeFrame': 'From the first occurrence of a documented confirmed objective response to disease progression or death from any cause, whichever occurs first (up to approximately 24 months)'}` to `{'measure': 'Investigator-assessed DOR in the FAS', 'description': 'DOR was defined as the time from the first occurrence of a documented OR (CR or PR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm.', 'timeFrame': 'From the first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[3]` changed from `{'measure': 'Investigator-Assessed Confirmed ORR in the FAS', 'description': 'ORR was defined as the percentage of participants with CR or PR as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.', 'timeFrame': 'From randomization up to approximately 24 months'}` to `{'measure': 'Investigator-assessed Confirmed ORR in the FAS', 'description': 'ORR was defined as the percentage of participants with CR or PR as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.', 'timeFrame': 'From randomization up to approximately 24 months'}`
    • Field `outcomesModule.secondaryOutcomes.[11]` changed from `{'measure': 'TTCD of EORTC QLQ-C30 Physical Functioning in the FAS', 'description': "TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in physical functioning. TTCD was determined based on patient-reported physical functioning (items 1-5) as collected and measured by the EORTC QLQ-C30. The PF is measured on 4-point scale (1='Not at all' to 4='Very much'). A high score for the physical function subscale represented a high/healthy level of functioning. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in physical functioning subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.", 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration up to approximately 24 months'}` to `{'measure': 'TTCD of EORTC QLQ-C30 Physical Functioning in the FAS', 'description': "TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in PF. TTCD was determined based on patient-reported PF (Items 1-5) as collected and measured by the EORTC QLQ-C30. The PF was measured on 4-point scale (1='Not at all' to 4='Very much'). A high score for the PF subscale represented a high/healthy level of functioning. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in PF subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.", 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[20]` changed from `{'measure': 'Number of Participants With ADAs to Atezolizumab', 'description': 'Reported here is the number of participants who had a positive ADA assay result at baseline and the number of participants positive for treatment emergent ADAs. The number of participants positive for treatment emergent ADAs includes treatment-induced and treatment-enhanced ADA positive participants. Treatment-induced ADAs are participants with negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADAs are participants with a positive ADA result at baseline who had one or more post-baseline titer results that were at least 0.60 t.u. greater than the baseline titer result. The total number of participants who developed ADAs to atezolizumab was determined by summing the ADA-positive participants across all timepoints.', 'timeFrame': 'Predose on Day 1 of Cycles 1 (each cycle is 21 days), 2, 3, 4, 8,12 and 16 and at TD visit (up to 24 months)'}` to `{'measure': 'Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab', 'description': 'Participants were considered to be ADA-positive if they were ADA-negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). The total number of participants who developed ADAs to tiragolumab was determined by summing the ADA-positive participants across all timepoints.', 'timeFrame': 'Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8,12, 16 and at treatment discontinuation (TD) visit (up to 24 months) (1 Cycle=21 days)'}`
    • Field `outcomesModule.secondaryOutcomes.[7]` changed from `{'measure': 'Investigator-Assessed PFS Rates at 6 Months and 12 Months in the FAS', 'description': 'PFS rate at 6 months and 12 months was defined as the percentage of participants who were event free at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate is a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value is calculated from ordered data (Event, Censoring) of each patient, using the Kaplan-Meier method, and accounts for censored observations( so Event free rates may not directly be calculated based only on patients remaining at risk).', 'timeFrame': 'Month 6, Month 12'}` to `{'measure': 'Investigator-assessed PFS Rates at 6 Months and 12 Months in the FAS', 'description': 'PFS rate at 6 months and 12 months was defined as the percentage of participants who were event-free at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the K-M method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).', 'timeFrame': 'Month 6, Month 12'}`
    • Field `outcomesModule.secondaryOutcomes.[9]` changed from `{'measure': 'Overall Survival Rates at 12 Months and 24 Months in the FAS', 'description': 'Overall survival rate at 12 months and 24 months was defined as the percentage of participants who were alive at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate is a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value is calculated from ordered data (Event, Censoring) of each patient, using the Kaplan-Meier method, and accounts for censored observations( so Event free rates may not directly be calculated based only on patients remaining at risk).', 'timeFrame': 'Month 12, Month 24'}` to `{'measure': 'OS Rates at 12 Months and 24 Months in the FAS', 'description': 'OS rate at 12 months and 24 months was defined as the percentage of participants who were alive at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the K-M method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).', 'timeFrame': 'Month 12, Month 24'}`
    • Field `outcomesModule.secondaryOutcomes.[2]` changed from `{'measure': 'Investigator-Assessed Confirmed Objective Response Rate (ORR) in the PAS', 'description': 'ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR.', 'timeFrame': 'From randomization up to approximately 24 months'}` to `{'measure': 'Investigator-assessed Confirmed Objective Response Rate (ORR) in the PAS', 'description': 'ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.', 'timeFrame': 'From randomization up to approximately 24 months'}`
    • Field `outcomesModule.secondaryOutcomes.[4]` changed from `{'measure': 'Investigator-Assessed Duration of Response (DOR) in the PAS', 'description': 'DOR was defined as the time from the first occurrence of a documented objective response (OR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR: was defined as disappearance of all target lesions or any pathological lymph nodes must have reduction in short axis to \\< 10 mm PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD= at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of \\>/= 5 mm.', 'timeFrame': 'From the first occurrence of a documented confirmed objective response to disease progression or death from any cause, whichever occurs first (up to approximately 24 months)'}` to `{'measure': 'Investigator-assessed Duration of Response (DOR) in the PAS', 'description': 'DOR was defined as the time from the first occurrence of a documented OR (CR or PR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\< 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm.', 'timeFrame': 'From the first occurrence of a documented confirmed objective response (OR) to PD or death from any cause, whichever occurred first (up to approximately 24 months)'}`
    • Field `outcomesModule.secondaryOutcomes.[12]` changed from `{'measure': 'TTCD of EORTC QLQ-C30 Global Health Status (GHS)/Quality of Life (QoL) in the PAS', 'description': 'TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in patient-reported global health status (GHS)/ quality of life (QoL). TTCD was determined based on patient-reported GHS/QoL (items 29-30) as collected and measured by the EORTC QLQ-C30. HS/QoL items are scored on a 7-point scale that ranges from "very poor" to "excellent". A high score for the GHS/QoL subscale represented a high health related quality of life. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in GHS/QoL subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.', 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration up to approximately 24 months'}` to `{'measure': 'TTCD of EORTC QLQ-C30 Global Health Status (GHS)/Quality-of-life (QoL) in the PAS', 'description': 'TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in patient-reported GHS/QoL. TTCD was determined based on patient-reported GHS/QoL (Items 29-30) as collected and measured by the EORTC QLQ-C30. GHS/QoL items were scored on a 7-point scale, ranging from "very poor" to "excellent". A high score for the GHS/QoL subscale represented a high health-related QoL. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in GHS/QoL subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.', 'timeFrame': 'From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)'}`
    • New field added: `root['outcomesModule']['otherOutcomes']`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[52]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[52]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[52]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT06989112

  • 2026-04-09 02:28:32 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-03` to `2026-04`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-11` to `2026-04-07`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-12` to `2026-04-08`
    • Field `contactsLocationsModule.locations.[4]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[70]city` changed from `Ghent` to `Oklahoma City`
    • Field `contactsLocationsModule.locations.[70]zip` changed from `9000` to `73104`
    • Field `contactsLocationsModule.locations.[70]country` changed from `Belgium` to `United States`
    • Field `contactsLocationsModule.locations.[70]geoPoint.lat` changed from `51.05` to `35.46756`
    • Field `contactsLocationsModule.locations.[70]geoPoint.lon` changed from `3.71667` to `-97.51643`
    • Field `contactsLocationsModule.locations.[54]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[88]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[139]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[143]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[149]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[167]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[208]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[229]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • New field added: `root['contactsLocationsModule']['locations'][70]['state']`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[173]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[173]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[173]geoPoint.lon` changed from `14.5195` to `14.26811`
  • 2026-03-13 02:09:20 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-09` to `2026-03-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-10` to `2026-03-12`
    • Field `contactsLocationsModule.locations.[5]status` changed from `NOT_YET_RECRUITING` to `SUSPENDED`
    • Field `contactsLocationsModule.locations.[16]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[18]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[19]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[28]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[45]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[51]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[67]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[73]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[81]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[103]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[139]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[141]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[143]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[144]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[146]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[160]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[168]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[172]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[177]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[208]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[220]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[227]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[229]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[230]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[232]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[233]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[243]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[244]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-02-12 14:01:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-14` to `2026-02-09`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-15` to `2026-02-10`
    • Field `contactsLocationsModule.locations.[11]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[46]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[57]zip` changed from `53705` to `53792`
    • Field `contactsLocationsModule.locations.[70]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[76]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[78]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[79]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[121]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[149]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[182]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[190]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[223]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[245]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT06627647

  • 2026-03-28 02:22:27 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-11` to `2026-03-26`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-12` to `2026-03-27`
    • Field `contactsLocationsModule.locations.[31]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[89]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[146]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[152]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[172]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[178]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[211]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-02-16 21:08:12 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-19` to `2026-02-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-22` to `2026-02-12`
    • Field `contactsLocationsModule.locations.[16]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[23]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[179]status` changed from `NOT_YET_RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[183]status` changed from `RECRUITING` to `WITHDRAWN`
    • Field `contactsLocationsModule.locations.[196]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[202]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[232]status` changed from `NOT_YET_RECRUITING` to `SUSPENDED`

NCT04305054

  • 2026-04-09 02:28:32 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-08` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-04-20` to `2026-05-20`
    • Field `statusModule.completionDateStruct.date` changed from `2026-04-20` to `2026-05-20`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-08-28` to `2026-04-07`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-08-29` to `2026-04-08`
  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[46]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[46]geoPoint.lat` changed from `45.40797` to `44.38225`
    • Field `contactsLocationsModule.locations.[46]geoPoint.lon` changed from `11.88586` to `11.14261`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[45]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[45]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[45]geoPoint.lon` changed from `14.5195` to `14.26811`

NCT04294810

  • 2026-04-04 02:21:52 (Trial Update)
    • Field `contactsLocationsModule.locations.[56]city` changed from `Padua` to `Padova`
    • Field `contactsLocationsModule.locations.[56]geoPoint.lat` changed from `45.40797` to `45.26618`
    • Field `contactsLocationsModule.locations.[56]geoPoint.lon` changed from `11.88586` to `11.77208`
  • 2026-03-21 02:05:10 (Trial Update)
    • Field `contactsLocationsModule.locations.[48]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[48]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[48]geoPoint.lon` changed from `14.5195` to `14.26811`

📥 Download Full Data (CSV) 📥 Download Status Summary (CSV)

Monitoring Status

Trial ID Sponsor Update Status Conditions Phases Start End Enroll Last Updated
NCT04818619 Assiut University No Change Unknown Chronic Myeloid Leukemia N/A 2021-04 2022-12 65 2021-03-25
NCT04150965 Multiple Myeloma Research Cons… No Change Terminated Multiple Myeloma, Relapsed Ref… PHASE1 PHASE2 2020-07-10 2024-08-30 14 2025-02-12
NCT05607563 Biotheus Inc. No Change Unknown Advanced Tumor PHASE1 2022-11-21 2023-12 54 2023-02-07
NCT05394168 Shanghai Henlius Biotech Changed Unknown Advanced/Metastatic Solid Tumo… PHASE1 2022-12-09 2025-03-04 12 2024-03-28
NCT07171307 Instituto de Oftalmología Fund… No Change Not Yet Recruiting Conjunctivitis, Allergic N/A 2026-01-01 2026-09 60 2025-09-15
NCT04995523 AstraZeneca Changed Active Not Recruiting Non-Small-Cell Lung Carcinoma PHASE1 PHASE2 2021-09-14 2028-06-01 212 2026-03-20
NCT03119428 OncoMed Pharmaceuticals, Inc. No Change Terminated Locally Advanced Cancer, Metas… PHASE1 2017-05-02 2019-05-15 33 2020-08-10
NCT04500678 University of Hawaii No Change Unknown HIV/AIDS PHASE2 PHASE3 2019-02-01 2022-12-31 38 2020-08-04
NCT05483400 University Medical Center Gron… No Change Recruiting Head and Neck Neoplasms, MSI-H… PHASE2 2023-10-18 2027-09 97 2025-03-28
NCT05390528 Shanghai Henlius Biotech No Change Unknown Advanced Tumors, Lymphoma, Met… PHASE1 PHASE2 2022-06-20 2024-12-30 30 2023-08-07
NCT06250036 Royal Marsden NHS Foundation T… No Change Recruiting Locally Advanced Gastric Adeno… PHASE2 2025-02-20 2031-09-01 50 2025-08-19
NCT05653284 Akeso No Change Completed Advanced Malignant Tumors PHASE1 2023-02-09 2024-05-30 19 2024-08-11
NCT05102214 Shanghai Henlius Biotech No Change Unknown Locally Advanced or Metastatic… PHASE1 PHASE2 2022-05-03 2024-02 150 2023-08-07
NCT05023109 Shanghai Zhongshan Hospital No Change Unknown Biliary Tract Carcinoma PHASE2 2021-02-01 2024-12-01 45 2023-08-12
NCT05130177 Diwakar Davar Changed Active Not Recruiting Melanoma PHASE2 2022-03-16 2030-01-31 8 2026-03-25
NCT04047862 BeiGene No Change Completed Locally Advanced and Metastati… PHASE1 2019-08-15 2024-08-07 446 2025-08-04
NCT05537051 Biotheus Inc. No Change Unknown Advanced Solid Tumours PHASE1 2023-10-30 2025-12-31 30 2023-02-07
NCT05019677 Fudan University No Change Withdrawn Intrahepatic Cholangiocarcinom… PHASE2 2021-09-01 2024-12-01 0 2022-03-22
NCT05061628 Shanghai Junshi Bioscience Co…. No Change Unknown Advanced Tumors PHASE1 2021-04-21 2024-09-30 176 2021-09-21
NCT04656535 Yale University No Change Active Not Recruiting Glioblastoma EARLY_PHASE1 2021-04-21 2026-12-31 46 2026-01-06
NCT06773507 Sichuan Luzhou Buchang Biophar… No Change Recruiting Advanced Esophageal Cancers, A… PHASE1 2025-05-12 2027-06 80 2025-07-07
NCT06349980 Shanghai Henlius Biotech No Change Recruiting Carcinoma, Hepatocellular PHASE2 2024-08-05 2027-02-10 117 2024-12-15
NCT05706207 Huabo Biopharm Co., Ltd. No Change Unknown Advanced Solid Tumor PHASE1 2021-12-21 2023-09-30 36 2023-01-20
NCT05060432 iTeos Belgium SA No Change Active Not Recruiting Advanced Cancer, Lung Cancer, … PHASE1 PHASE2 2021-09-06 2025-07 153 2024-06-19
NCT06713798 Gustave Roussy, Cancer Campus,… Changed Withdrawn Metastatic Cancer Lung, Advanc… PHASE2 2025-01-30 2025-09-15 0 2026-03-19
NCT05394337 M.D. Anderson Cancer Center No Change Recruiting Metastatic Malignancy PHASE1 PHASE2 2023-02-23 2025-12-31 10 2025-10-07
NCT05253105 Shanghai Junshi Bioscience Co…. No Change Withdrawn Previously Treated, Advanced, … PHASE1 2022-03-15 2027-01 0 2022-05-24
NCT04270942 Provention Bio, a Sanofi Compa… No Change Completed Diabetes Mellitus, Type 1 PHASE2 2020-02-26 2024-01-22 6 2025-01-20
NCT05294952 Assiut University No Change Unknown Pre-Eclampsia PHASE4 2025-01-01 2025-11-04 82 2024-02-01
NCT06754501 M.D. Anderson Cancer Center No Change Active Not Recruiting Cancer PHASE2 2025-04-11 2029-07-01 4 2026-02-16
NCT05757492 Coherus Oncology, Inc. No Change Terminated Advanced Solid Tumor, Non-Smal… PHASE1 2023-04-26 2024-07-31 22 2025-04-30
NCT04952597 BeiGene No Change Completed Limited Stage Small Cell Lung … PHASE2 2021-07-15 2023-07-26 126 2024-10-23
NCT05805501 Hoffmann-La Roche No Change Active Not Recruiting Renal Cell Carcinoma PHASE2 2023-04-21 2026-10-31 199 2026-02-10
NCT03447678 Fondazione IRCCS Istituto Nazi… No Change Unknown Non Small Cell Lung Cancer (NS… PHASE2 2018-05-23 2022-05-31 65 2021-06-08
NCT04672369 Innovent Biologics (Suzhou) Co… No Change Completed Advanced Lung Cancer PHASE1 2021-06-06 2023-06-01 42 2023-06-18
NCT04672356 Innovent Biologics (Suzhou) Co… No Change Completed Advanced Lung Cancer PHASE1 2021-01-25 2023-06-01 19 2023-06-18
NCT05009069 Hoffmann-La Roche No Change Active Not Recruiting Rectal Neoplasms, Rectal Cance… PHASE2 2022-03-18 2026-11-06 58 2026-01-16
NCT04353830 Innovent Biologics (Suzhou) Co… No Change Completed Advanced Malignancies PHASE1 2020-05-22 2022-05-11 34 2023-02-28
NCT07337447 Hospices Civils de Lyon No Change Not Yet Recruiting Carcinoma, Neuroendocrine PHASE2 2026-04 2030-04 122 2026-01-07
NCT04354246 Compugen Ltd No Change Active Not Recruiting Advanced Cancer, Ovarian Cance… PHASE1 2020-03-31 2025-12-30 110 2025-05-18
NCT04933227 Hoffmann-La Roche No Change Terminated Stomach Neoplasms, Gastric Can… PHASE2 2021-08-06 2023-11-17 29 2024-11-11
NCT05414032 University Health Network, Tor… No Change Recruiting Locoregionally Advanced Head a… PHASE2 2023-07-12 2028-07 102 2026-02-23
NCT06003621 Omico No Change Recruiting Solid Tumor, Adult PHASE2 2023-12-15 2028-11-01 96 2024-11-13
NCT05568095 Arcus Biosciences, Inc. Changed Active Not Recruiting Advanced Upper Gastrointestina… PHASE3 2022-11-21 2026-06 1,040 2026-03-31
NCT06777628 IRCCS Azienda Ospedaliero-Univ… No Change Recruiting Liver Cancer, Adult N/A 2024-09-15 2028-10-15 100 2025-01-14
NCT06773481 Sichuan Luzhou Buchang Biophar… No Change Recruiting Glioma, Glioma Tumor Recurrenc… PHASE1 2025-04-07 2026-12 40 2025-07-07
NCT03708224 Alain Algazi No Change Recruiting Cancer, Carcinoma, Squamous Ce… PHASE2 2019-03-08 2028-06-30 55 2025-01-24
NCT03652402 Assistance Publique - Hôpitaux… No Change Completed Kidney Transplant Rejection, K… N/A 2018-11-27 2021-10-28 558 2024-06-04
NCT03486119 Yonsei University No Change Completed Non -Small Cell Lung Cancer N/A 2018-02-05 2020-07-07 60 2020-10-14
NCT05120375 Bio-Thera Solutions No Change Terminated Solid Tumor PHASE1 2022-02-17 2023-04-07 5 2023-10-08
NCT05327530 EMD Serono Research & Developm… Changed Active Not Recruiting Locally Advanced or Metastatic… PHASE2 2022-08-17 2026-06-25 256 2026-01-23
NCT04570839 Compugen Ltd No Change Completed Endometrial Neoplasms, Ovarian… PHASE1 PHASE2 2020-08-31 2024-05-15 48 2024-07-17
NCT05520294 University of Colorado, Denver No Change Active Not Recruiting Melanoma N/A 2022-09-01 2024-08-31 90 2024-04-15
NCT05417321 Shanghai Huaota Biopharmaceuti… No Change Recruiting Advanced Solid Tumor, NSCLC PHASE1 PHASE2 2022-08-25 2025-08-01 80 2025-01-02
NCT06328036 National Cancer Institute (NCI… No Change Withdrawn Recurrent Glioblastoma, IDH-Wi… PHASE2 2025-04-30 2025-07-01 0 2024-12-27
NCT04465643 Sidney Kimmel Comprehensive Ca… No Change Completed Nerve Sheath Tumors PHASE1 2021-06-08 2025-07-30 13 2025-10-02
NCT04262856 Arcus Biosciences, Inc. No Change Completed Non Small Cell Lung Cancer, No… PHASE2 2020-05-28 2025-07-09 151 2025-08-25
NCT04736173 Arcus Biosciences, Inc. Changed Active Not Recruiting Non Small Cell Lung Cancer, No… PHASE2 2021-02-08 2027-05 169 2026-03-27
NCT05126537 Southeast University, China No Change Unknown 28 Day Mortality N/A 2022-01-01 2022-12-31 100 2022-11-25
NCT05289492 iTeos Therapeutics No Change Terminated Multiple Myeloma PHASE1 2022-05-01 2023-11-29 16 2024-10-23
NCT07115043 AstraZeneca Changed Recruiting Melanoma, Non-small Cell Lung … PHASE1 PHASE2 2025-07-29 2029-10-02 60 2026-03-16
NCT05743504 National Taiwan University Hos… No Change Unknown Locally Advanced Esophageal Sq… PHASE1 PHASE2 2023-09-18 2025-11-30 32 2024-01-31
NCT05073484 Bio-Thera Solutions No Change Terminated Advanced Solid Tumor PHASE1 2021-10-29 2023-03-30 13 2023-10-09
NCT07376512 Centre Georges Francois Lecler… No Change Not Yet Recruiting Non-Small Cell Lung Cancer, Me… N/A 2026-03-01 2030-03-01 378 2026-01-22
NCT05904886 Hoffmann-La Roche No Change Active Not Recruiting Hepatocellular Carcinoma PHASE3 2023-09-14 2026-09-01 687 2025-12-30
NCT03739710 GlaxoSmithKline Changed Completed Neoplasms PHASE2 2019-01-24 2024-05-02 175 2025-06-13
NCT04791839 Washington University School o… No Change Active Not Recruiting Non Small Cell Lung Cancer, No… PHASE2 2021-08-04 2030-06-30 30 2025-11-04
NCT05020912 Case Comprehensive Cancer Cent… No Change Recruiting Basal Cell Carcinoma PHASE2 2021-12-13 2027-12 28 2025-11-25
NCT06334406 Centre Hospitalier Universitai… Changed Unknown Bladder Cancer N/A 2024-04-02 2026-04-02 33 2024-03-19
NCT07343310 Kine Sciences Co., Ltd. No Change Completed CIDP - Chronic Inflammatory De… PHASE1 2024-08-27 2025-04-14 9 2026-01-15
NCT03342417 ExcellaBio LLC No Change Terminated Breast Cancer Female, Ovarian … PHASE2 2018-02-14 2019-05-29 5 2021-11-05
NCT04682665 University of Leeds No Change Completed Colon Cancer Liver Metastasis N/A 2021-09-16 2024-07-31 81 2024-12-03
NCT05123482 AstraZeneca Changed Recruiting Breast Cancer, Biliary Tract C… PHASE1 PHASE2 2021-10-18 2027-09-29 460 2026-03-20
NCT07161414 AstraZeneca Changed Recruiting Advanced Solid Tumors PHASE1 2025-11-25 2029-07-24 40 2026-04-08
NCT07015164 Assistance Publique - Hôpitaux… No Change Not Yet Recruiting HIV N/A 2025-06-10 2026-09-11 80 2025-06-03
NCT05702229 AstraZeneca Changed Recruiting Gastric Cancer PHASE2 2023-01-16 2029-05-31 163 2026-03-16
NCT07213882 Assistance Publique - Hôpitaux… No Change Not Yet Recruiting Cutaneous T Cell Lymphoma (CTC… EARLY_PHASE1 2026-01-01 2028-08-01 30 2025-10-02
NCT03628677 Arcus Biosciences, Inc. No Change Completed Solid Tumor, Unspecified, Adul… PHASE1 2018-09-12 2025-01-23 75 2025-02-03
NCT06897436 Medical University of Lublin No Change Not Yet Recruiting Endometriosis N/A 2025-05-01 2029-12-31 60 2025-03-24
NCT05633927 Hospitales Universitarios Virg… No Change Completed SARS-CoV-2 RNA Vaccines, HIV I… N/A 2021-04-01 2022-12-01 48 2024-10-09
NCT04836507 Curocell Inc. No Change Recruiting Relapsed Large B-cell Lymphoma… PHASE1 PHASE2 2021-03-02 2028-02 91 2021-04-29
NCT05775159 AstraZeneca Changed Recruiting Hepatocellular Carcinoma, Bili… PHASE2 2023-04-24 2027-10-28 294 2026-02-16
NCT06338657 University of Southern Califor… No Change Terminated Head and Neck Squamous Cell Ca… PHASE1 2024-04-01 2025-09-09 1 2025-09-09
NCT06860815 City of Hope Medical Center No Change Recruiting Anatomic Stage IV Breast Cance… PHASE2 2026-04-01 2027-01-30 11 2026-01-27
NCT04624828 Istituto Clinico Humanitas No Change Active Not Recruiting Oligorecurrent and Oligoprogre… NA 2020-10-19 2026-07 40 2025-04-22
NCT05574335 National Institute of Allergy … No Change Terminated Type 1 Diabetes Mellitus PHASE1 PHASE2 2023-04-26 2025-10-20 8 2026-02-10
NCT06302556 Fondazione IRCCS Ca' Granda, O… Changed Unknown Lung Transplant Rejection N/A 2024-04 2026-02 280 2024-03-06
NCT04761198 Mereo BioPharma No Change Completed Solid Tumor, Adult, Advanced S… PHASE1 PHASE2 2021-03-23 2023-10-30 76 2025-03-07
NCT04693234 BeiGene No Change Completed Cervical Cancer PHASE2 2021-02-15 2023-08-31 178 2025-04-09
NCT03563716 Genentech, Inc. No Change Completed Non-small Cell Lung Cancer PHASE2 2018-08-10 2025-11-24 135 2025-12-30
NCT07324642 Kine Sciences Co., Ltd. No Change Completed Healthy Volunteers PHASE1 2025-05-26 2025-08-25 24 2025-12-24
NCT05809895 Novartis Pharmaceuticals No Change Withdrawn Triple Negative Breast Cancer PHASE2 2023-09-15 2029-07-18 0 2023-07-21
NCT04732494 BeiGene No Change Completed Esophageal Squamous Cell Carci… PHASE2 2021-03-31 2023-12-26 125 2024-12-23
NCT05645692 Hoffmann-La Roche Changed Active Not Recruiting Urothelial Cancer PHASE2 2023-04-13 2026-12-31 204 2026-01-28
NCT04457778 EMD Serono Research & Developm… No Change Completed Metastatic Solid Tumors PHASE1 2020-07-10 2023-06-23 58 2023-12-07
NCT03772899 London Health Sciences Centre … No Change Active Not Recruiting Melanoma PHASE1 2019-03-27 2026-08 20 2025-03-26
NCT04374877 Coherus Oncology, Inc. No Change Completed Advanced Solid Tumor, Clear Ce… PHASE1 2020-04-22 2025-06-05 145 2025-11-06
NCT06346197 Centre Leon Berard Changed Recruiting Gastric Cancer, MSI-H, Metasta… PHASE3 2025-12-08 2028-05-15 132 2026-04-02
NCT05780073 Fundació Institut Germans Tria… No Change Completed HIV Infection Primary PHASE2 2023-10-16 2025-04-01 60 2025-09-16
NCT03667716 Compugen Ltd No Change Completed Advanced Cancer, Ovarian Cance… PHASE1 2018-09-06 2024-01-30 121 2025-01-15
NCT06784947 University of Colorado, Denver No Change Active Not Recruiting Microsatellite Stable (MSS) Co… PHASE2 2025-03-25 2028-05 13 2025-10-01
NCT05014815 BeiGene No Change Completed Locally Advanced, Unresectable… PHASE2 2021-11-16 2024-09-04 272 2025-08-28
NCT07307053 Cancer Institute and Hospital,… No Change Not Yet Recruiting Rare Malignant Neoplasm, Advan… PHASE1 PHASE2 2026-01-01 2031-01-31 600 2025-12-13
NCT04746924 BeiGene No Change Active Not Recruiting Non-small Cell Lung Cancer, NS… PHASE3 2021-06-08 2026-03-31 662 2025-06-23
NCT07098338 AstraZeneca No Change Recruiting Non-Small Cell Lung Cancer PHASE2 2025-08-07 2029-04-06 278 2026-02-03
NCT06532539 Shandong Cancer Hospital and I… No Change Recruiting Endometrial Neoplasms, Neoplas… PHASE2 2024-06-13 2026-05 30 2024-07-29
NCT06864598 Peking University People's Hos… No Change Enrolling By Invitation Graft-versus-host Disease (GVH… N/A 2025-01-09 2026-10-31 100 2025-03-04
NCT03661047 Massachusetts General Hospital No Change Withdrawn Colon Cancer PHASE2 2019-11-30 2021-11-30 0 2021-11-10
NCT04866017 BeiGene No Change Terminated Non Small Cell Lung Cancer PHASE3 2021-06-17 2023-10-17 63 2024-10-09
NCT05127824 Jodi Maranchie No Change Recruiting Carcinoma, Renal Cell PHASE2 2023-07-06 2026-12 42 2025-04-30
NCT04303169 Merck Sharp & Dohme LLC No Change Completed Melanoma PHASE1 PHASE2 2020-06-26 2025-09-24 146 2025-10-23
NCT05329766 Arcus Biosciences, Inc. Changed Active Not Recruiting Gastrointestinal Tract Maligna… PHASE2 2022-06-10 2027-06 332 2026-03-27
NCT04323202 Case Comprehensive Cancer Cent… No Change Completed Basal Cell Carcinoma of the He… PHASE1 2020-08-04 2025-06-25 13 2025-10-23
NCT07221253 AstraZeneca Changed Recruiting Biliary Tract Cancer PHASE3 2025-12-04 2029-07-04 1,100 2026-03-16
NCT05676931 Gilead Sciences Changed Active Not Recruiting Advanced Non-Small Cell Lung C… PHASE2 2023-02-21 2027-12 400 2025-09-29
NCT06790706 Hospices Civils de Lyon No Change Recruiting Peritoneal Mesothelioma, Gesta… PHASE2 2025-10-01 2031-06 154 2025-10-01
NCT04543617 Hoffmann-La Roche Changed Active Not Recruiting Esophageal Squamous Cell Carci… PHASE3 2020-09-28 2027-03-31 760 2026-01-16
NCT04305041 Merck Sharp & Dohme LLC Changed Completed Melanoma PHASE1 PHASE2 2020-06-26 2025-08-25 100 2025-08-28
NCT06996782 AstraZeneca Changed Recruiting Advanced or Metastatic Non-sma… PHASE1 PHASE2 2025-11-24 2029-02-23 152 2026-03-27
NCT05665595 Merck Sharp & Dohme LLC Changed Completed Melanoma PHASE3 2023-01-19 2025-09-26 1,594 2025-10-03
NCT06868277 AstraZeneca Changed Recruiting Carcinoma, Non-Small Cell Lung PHASE3 2025-04-10 2030-12-02 830 2026-02-27
NCT06692738 AstraZeneca Changed Recruiting Non-small Cell Lung Cancer PHASE3 2024-11-18 2029-10-08 880 2026-03-30
NCT04774484 Francesc Marti No Change Withdrawn End Stage Renal Disease NA 2023-01 2026-06-30 0 2023-02-10
NCT04256421 Hoffmann-La Roche Changed Completed Small Cell Lung Cancer PHASE3 2020-02-04 2025-07-31 490 2026-03-13
NCT06989112 AstraZeneca Changed Recruiting Endometrial Cancer PHASE3 2025-03-27 2031-02-19 600 2026-04-07
NCT05816460 University College Dublin No Change Unknown Insomnia, Cancer NA 2023-05-22 2024-06-10 308 2023-05-19
NCT06627647 AstraZeneca Changed Recruiting Non-squamous Non-small Cell Lu… PHASE3 2024-11-27 2030-03-25 878 2026-03-26
NCT04305054 Merck Sharp & Dohme LLC Changed Active Not Recruiting Melanoma PHASE1 PHASE2 2020-07-01 2026-05-20 315 2026-04-07
NCT04294810 Hoffmann-La Roche Changed Completed Non-Small Cell Lung Cancer PHASE3 2020-03-04 2025-12-30 620 2026-01-29
NCT03198546 Second Affiliated Hospital of … No Change Recruiting Hepatocellular Carcinoma, Immu… PHASE1 2017-07-01 2036-08-01 30 2024-06-22
NCT03198052 Second Affiliated Hospital of … No Change Recruiting Lung Cancer, Cancer, Immunothe… PHASE1 2017-07-01 2036-08-01 30 2024-06-22
NCT04585815 Pfizer No Change Terminated Carcinoma, Non-Small-Cell Lung PHASE1 PHASE2 2020-11-10 2024-10-29 34 2025-12-18
NCT02443155 Novo Nordisk A/S No Change Completed Diabetes, Diabetes Mellitus, T… PHASE2 2015-11-10 2019-02-27 308 2021-03-10